Intellectual Property

MLD is the legal owner of patents relating to the composition of matter, use and synthesis of plasmalogen precursor compounds including PPI-1040, PPI-1011, and multiple other configurations. MLD also owns patents for the measurement of plasmalogens as a risk factor for Alzheimer’s disease, dementia, Parkinsons’s disease, Multiple Sclerosis, Rhizomelic Chondrodyaplasia Punctata, and any conditions associated with a plasmalogen deficiency.

IF YOU ARE INTERESTED IN LICENSING RIGHTS TO EITHER THE SYNTHESIS OF PLASMALOGEN PRECURORS OR THE RIGHTS TO MEASURE PLASMALOGENS FOR SCREENING OR DIAGNOSTIC PURPOSES, CONTACT US HERE.

PATENTS LEGALLY OWNED BY MED-LIFE DISCOVERIES

The primary inventors on some of these patents were previous employees of Phreedom Pharma Inc., a subsidiary of Phenomenome Discoveries Inc. that was purchased by MLD in 2016. These patents are now exclusively owned by MLD.

Methods For The Synthesis Of Plasmalogens And Plasmalogen Derivatives, And Therapeutic Uses Thereof.

This patent describes routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).